89107-70-0

Usage

Uses

Used in Pharmaceutical Applications:
L-Glutamic acid, L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-pentakis(phenylmethyl) ester is used as a pharmaceutical agent for its potential antioxidant and neuroprotective effects. Its ability to protect cells from oxidative stress and support neuronal health makes it a valuable compound in the development of treatments for neurodegenerative diseases and other conditions related to oxidative damage.
Used in Drug Delivery Systems:
In the field of drug delivery, L-Glutamic acid, L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-pentakis(phenylmethyl) ester is utilized as a carrier molecule for enhancing the bioavailability and cellular uptake of therapeutic agents. Its capacity to penetrate cell membranes allows for improved delivery of drugs to target sites, increasing the efficacy of treatments and reducing side effects.
Used in Research Applications:
L-Glutamic acid, L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-pentakis(phenylmethyl) ester is also used in research settings to explore its full potential and possible uses in various fields. Ongoing studies aim to uncover its biological activities, interactions with other molecules, and potential applications in the development of new therapies and diagnostic tools.

Upstream product

• 89107-69-7 Boc-Glu(OBzl)4-OBzl 
• 13574-13-5 Boc-Glu(OBzl)-OH 
• 82082-83-5 H-Glu(OBzl)-Glu(OBzl)-OBzl 
• 89092-61-5 N-tertbutyloxycarbonyl dipeptide of benzyl glutamate 
• 121445-54-3 Boc-Glu(OBzl)3-OBzl 
• 2768-50-5 dibenzyl L-glutamate 

Downstream Products

• 146552-87-6 (S)-2-{(S)-4-Benzyloxycarbonyl-2-[(S)-4-benzyloxycarbonyl-2-((S)-4-benzyloxycarbonyl-2-octanoylamino-butyrylamino)-butyrylamino]-butyrylamino}-pentanedioic acid dibenzyl ester 
• 146552-80-9 (S)-2-((S)-4-Benzyloxycarbonyl-2-{(S)-4-benzyloxycarbonyl-2-[(S)-4-benzyloxycarbonyl-2-((S)-4-benzyloxycarbonyl-2-tert-butoxycarbonylamino-butyrylamino)-butyrylamino]-butyrylamino}-butyrylamino)-pentanedioic acid dibenzyl ester 
• 128302-97-6 Boc-dmaPhe-Glu(OBzl)4-OBzl 
• 128302-91-0 napAla-Glu(OBzl)4-OBzl 
• 128302-96-5 Boc-napAla-Glu(OBzl)4-OBzl 

Relevant academic research and scientific papers

Synthesis and preliminary evaluation of novel bone-targeting NSAIDs prodrugs based on glutamic acid oligopeptides

Osteoarthritis is no doubt a difficult disease to manage. Targeted delivery of drugs to bone may not only enhance the treatment efficacy, but also reduces the quantity of drug administered. In this paper, we have synthesized two series of NSAID-Glu oligop

Supramolecular aggregates formed by L-glutamic acid-oligomers: SANS and SAXS studies of the hydrogen bonded self-assembly

N-Acetyl-L-glutamic acid oligomeric benzyl esters with various residue numbers (NP = 4, 5, 6, 8, 10, 12 and 14) have been synthesized by a stepwise procedure. The microstructures of these oligopeptide aggregates in dioxane or benzene have been

Long-Distance Singlet Energy Transfer along α-Helical Polypeptide Chains

α-Helical polypeptides carrying L-4-biphenylalanine and L-1-naphthylalanine that are separated by up to 11 amino acid units or 19.5 Angstroem were prepared by stepwise peptide synthesis.Singlet energy transfer from the biphenyl group to the napthyl group

The β-Type Structures of Very Simple N-Octanoyl-L-glutamic Acid Oligomers (Residue Number, N = 2 - 6) and Their β1 -> β2 - Type Transition

N-Octanoyl-L-glutamic acid oligomers (residue number, N = 2 - 6) have been synthesized in order to study their molecular conformations in the solid state.The X-ray powder diffraction patterns and vibrational spectra of these oligomers have been investigat